Dr. Elizabeth Mittendorf discusses findings that suggest HER2-positive breast tumors can convert to HER2-negative status in women receiving
chemotherapy and the HER2-targeting
drug trastuzumab (Herceptin). Kerri Wachter of Elsevier Global Medical News (EGMN) interviews Dr. Mittendorf at a breast cancer symposium sponsored by the American Society for Clinical Oncology.
All Comments